Taeun Kang: Beyond Traditional ‘Blood Thinners’ – Cardiovascular and Thrombosis Therapeutics
Taeun Kang, Founder and Chief Growth Officer of Manhattan Signal, shared a post on LinkedIn:
“Pause and Note – Cardiovascular and Thrombosis Therapeutics
As shared previously, I have been spending more time independently researching cardiovascular therapeutics, thrombosis prevention, and emerging RNA-based medicines simply out of personal interest and curiosity around where the biotech and pharmaceutical industries may be heading.
Based on my research, below is a high-level market snapshot that I thought some people in biotech/pharma – and especially families impacted by cardiovascular conditions – may also find interesting.
It appears that the landscape is evolving beyond traditional ‘blood thinners’ into much more targeted next-generation cardiovascular approaches.
Current leaders still include major anticoagulants and antiplatelet therapies such as:
- Eliquis
- Xarelto
- Pradaxa
- Plavix
- Brilinta
At the same time, increasing attention appears to be shifting toward:
- Lp(a)-lowering therapies
- FXIa inhibitors
- RNA-based cardiovascular medicines
- Precision thrombosis prevention
Particularly interesting is the growing focus around Lipoprotein(a) [Lp(a)], which continues drawing attention in cardiovascular risk and thrombosis research.
Some major programs currently being watched across the industry include:
- Pelacarsen – Novartis
- Olpasiran – Amgen
- Zerlasiran – Silence Therapeutics
- Lepodisiran – Eli Lilly
I also found it fascinating how multiple modalities are emerging simultaneously, including:
- siRNA
- Antisense oligonucleotides (ASO)
- FXIa inhibition pathways
The intersection of RNA therapeutics, cardiovascular medicine, and preventative care may become one of the more important biotech themes of the next decade.
Question: How can we speed up these new emerging therapies?
To be continued”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis